secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001683168-22-007476
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences reports Q3 2022 net loss of $0.8M; cash of $13.8M
---------------------------------------------------------------------

- Net loss for Q3 2022 was approximately $0.8 million.
- R&D expenses fell 48.9% YoY to $0.4 million, reflecting shift from XCART to DNase platform.
- G&A expenses decreased 8.7% to $863,000.
- Cash and cash equivalents were $13.8 million at quarter-end; expected to fund operations and pipeline development.
- DNase oncology platform advancing toward first-in-human study for pancreatic carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316822007476/0001683168-22-007476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316822007476/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-007476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer